Drug Profile
Research programme: aptamer-based therapeutics - Archemix/Eli Lilly and Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer Eli Lilly and Company
- Class Oligonucleotides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 21 Oct 2008 Early research in Undefined indication in USA (unspecified route)